Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder
Conditions
Interventions
Intervention 1: Fluvoxamine 100 mg BID+ Amantadin 100mg/day for 10 weeks as intervention group. Intervention 2: Fluvoxamine 100 mg BID + placebo for 10 weeks as control group.
Treatment - Drugs
Placebo
Fluvoxamine 100 mg BID+ Amantadin 100mg/day for 10 weeks as intervention group
Fluvoxamine 100 mg BID + placebo for 10 weeks as control group
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1- Age between 18-60 years old; 2- Diagnosis of OCD based on DSM-5; 3- Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale. Exclusion Criteria: 1- Substance dependence; 2- IQ <70; 3- Any other mental disorder on axis I; 4-Any serious cardiac, renal or hepatic disease; 5- receiving psychotropic medications during the last 6 weeks; 6- pregnancy or breast feeding; 7- Rising liver transaminases to three times the upper limit of normal or higher.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of symptoms of OCD. Timepoint: Baseline and weeks: 2, 4, 6, 8, 10 after beginig of treatment. Method of measurement: Y_BOCS( Yale-Brown obsessive compulsive scale). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed